CN110997713B - 抗bet v 1人抗体及其使用方法 - Google Patents

抗bet v 1人抗体及其使用方法 Download PDF

Info

Publication number
CN110997713B
CN110997713B CN201880049949.7A CN201880049949A CN110997713B CN 110997713 B CN110997713 B CN 110997713B CN 201880049949 A CN201880049949 A CN 201880049949A CN 110997713 B CN110997713 B CN 110997713B
Authority
CN
China
Prior art keywords
seq
bet
antibody
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880049949.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110997713A (zh
Inventor
J·M·奥伦戈
A·J·莫菲
A·T·巴迪斯
V·卡玛
Y·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN110997713A publication Critical patent/CN110997713A/zh
Application granted granted Critical
Publication of CN110997713B publication Critical patent/CN110997713B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201880049949.7A 2017-06-01 2018-05-31 抗bet v 1人抗体及其使用方法 Active CN110997713B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US62/513,872 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US62/571,696 2017-10-12
US201862662165P 2018-04-24 2018-04-24
US62/662,165 2018-04-24
PCT/US2018/035366 WO2018222854A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (2)

Publication Number Publication Date
CN110997713A CN110997713A (zh) 2020-04-10
CN110997713B true CN110997713B (zh) 2024-01-02

Family

ID=62705709

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049949.7A Active CN110997713B (zh) 2017-06-01 2018-05-31 抗bet v 1人抗体及其使用方法

Country Status (17)

Country Link
US (3) US10793624B2 (enExample)
EP (1) EP3630814A1 (enExample)
JP (3) JP6963036B2 (enExample)
KR (3) KR102329175B1 (enExample)
CN (1) CN110997713B (enExample)
AU (2) AU2018275657B2 (enExample)
BR (1) BR112019025150B1 (enExample)
CA (2) CA3302765A1 (enExample)
CL (3) CL2019003508A1 (enExample)
CO (1) CO2019013196A2 (enExample)
IL (2) IL270894B2 (enExample)
MX (2) MX2019014430A (enExample)
MY (1) MY198270A (enExample)
NZ (1) NZ759513A (enExample)
PH (1) PH12019550238A1 (enExample)
WO (1) WO2018222854A1 (enExample)
ZA (1) ZA201907513B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
US11897945B2 (en) * 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
CN121241065A (zh) 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) * 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025117894A2 (en) * 2023-11-29 2025-06-05 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
WO2025165851A1 (en) 2024-01-30 2025-08-07 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies
WO2026125663A2 (en) * 2024-12-11 2026-06-18 Mabylon Ag Anti-allergen antibodies and uses thereof
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
WO2007134350A2 (en) * 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3036543B1 (en) * 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
US11897945B2 (en) * 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
WO2007134350A2 (en) * 2006-05-18 2007-11-29 Biomay Ag Antibodies specific for bet v 1 and use thereof in the prevention and treatment of bet v 1-induced diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1;V Visco等;《J Immunol》;19960715;第157卷(第2期);第956-962页 *
Isolation of high-affinity human IgE and IgG antibodies recognising Bet v 1 and Humicola lanuginosa lipase from combinatorial phage libraries;Charlotte GJakobsen等;《Mol Immunol》;20040801;第41卷(第10期);第941-953页 *
Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction;S Denépoux等;《FEBS Lett》;20000107;第465卷(第1期);第39-46页 *

Also Published As

Publication number Publication date
EP3630814A1 (en) 2020-04-08
AU2018275657B2 (en) 2022-01-06
CL2019003508A1 (es) 2020-06-19
US20180346555A1 (en) 2018-12-06
IL270894B (en) 2022-12-01
KR102878718B1 (ko) 2025-10-31
AU2018275657A1 (en) 2019-12-19
KR20200012892A (ko) 2020-02-05
NZ759513A (en) 2022-01-28
JP2020523004A (ja) 2020-08-06
AU2022200272B2 (en) 2024-10-03
BR112019025150B1 (pt) 2022-11-08
JP7162097B2 (ja) 2022-10-27
CL2021002850A1 (es) 2022-06-24
MY198270A (en) 2023-08-18
KR102674000B1 (ko) 2024-06-11
MX2023000390A (es) 2023-02-13
JP2022174238A (ja) 2022-11-22
KR102329175B1 (ko) 2021-11-19
AU2022200272A1 (en) 2022-02-10
US10793624B2 (en) 2020-10-06
MX2019014430A (es) 2020-07-14
KR20240096746A (ko) 2024-06-26
PH12019550238A1 (en) 2020-10-19
IL298034B2 (en) 2024-05-01
IL298034B1 (en) 2024-01-01
CA3302765A1 (en) 2026-05-13
IL270894A (en) 2020-01-30
JP2021112207A (ja) 2021-08-05
IL298034A (en) 2023-01-01
US11767358B2 (en) 2023-09-26
CN110997713A (zh) 2020-04-10
WO2018222854A1 (en) 2018-12-06
IL270894B2 (en) 2023-04-01
NZ782911A (en) 2025-08-29
US20240083986A1 (en) 2024-03-14
BR112019025150A2 (pt) 2020-06-23
JP7458453B2 (ja) 2024-03-29
ZA201907513B (en) 2022-04-28
CO2019013196A2 (es) 2020-01-17
CA3063588A1 (en) 2018-12-06
CL2021002851A1 (es) 2022-08-19
JP6963036B2 (ja) 2021-11-05
KR20210143327A (ko) 2021-11-26
US20210054056A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
AU2022200272B2 (en) Human antibodies to Bet v 1 and methods of use thereof
CN110240651B (zh) 针对fel d1的人源抗体及其使用方法
KR102780485B1 (ko) 염증 질환의 치료 방법
DK2187964T3 (en) HIGH AFFINE HUMAN ANTIBODIES FOR HUMAN NERVOUS FACTOR
KR101896129B1 (ko) 인간 tnf-유사 리간드 1a(tl1a)에 대한 인간 항체
KR101599706B1 (ko) 사람 ｉｌ-4 수용체에 대한 고 친화성 사람 항체
KR20090088936A (ko) 사람 델타 유사 리간드 4에 대한 사람 항체
KR20120059611A (ko) 인간 프로테아제-활성화된 수용체-2에 대한 고친화도 인간 항체들
EA049718B1 (ru) Фармацевтическая композиция, содержащая антитела человека к bet v 1, и способы ее применения
EA045437B1 (ru) Антитела человека к bet v 1 и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant